48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection

Mise à jour : Il y a 4 ans
Référence : NCT00114361

Femme et Homme

  • | Pays :
  • Netherlands
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The purpose of this study is to investigate whether in patients with chronic HBeAg-negative hepatitis B, PEG-IFN-ribavirin combination therapy for 1 year leads to enhanced response (HBV DNA <10E4 copies/ml and normal ALT 24 weeks after treatment discontinuation) in comparison with pegylated interferon (PEG-IFN) monotherapy.


Critère d'inclusion

  • Hepatitis B

Liens